1,100
Participants
Start Date
July 27, 2023
Primary Completion Date
December 31, 2026
Study Completion Date
June 30, 2027
LTOWB
Participants will receive Low Titer O Whole Blood administered intravenously or intraosseously.
Components
Participants will receive separated blood components (i.e., units of red cells, plasma, platelets, and cryoprecipitate) co-administered intravenously or intraosseously.
NOT_YET_RECRUITING
Penn Presbyterian Medical Center, Philadelphia
NOT_YET_RECRUITING
University of Maryland Medical Center, Baltimore
NOT_YET_RECRUITING
Atrium Health Wake Forest Baptist, Winston-Salem
RECRUITING
University of Alabama at Birmingham, UAB Hospital, Birmingham
RECRUITING
University of Cincinnati Medical Center, Cincinnati
NOT_YET_RECRUITING
Froedtert Hospital, Milwaukee
NOT_YET_RECRUITING
Washington University School of Medicine, St Louis
NOT_YET_RECRUITING
University Medical Center New Orleans LCMC Health, New Orleans
NOT_YET_RECRUITING
University of Texas Health Science Center Houston, Houston
NOT_YET_RECRUITING
University of Texas Health San Antonio and University Health System, San Antonio
NOT_YET_RECRUITING
Los Angeles County + University of Southern California (LAC + USC) Medical Center, Los Angeles
NOT_YET_RECRUITING
Oregon Health and Sciences University Hospital, Portland
RECRUITING
Harborview Medical Center, Seattle
National Heart, Lung, and Blood Institute (NHLBI)
NIH
The University of Texas Health Science Center, Houston
OTHER
University of Alabama at Birmingham
OTHER